Volume 19 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(8): 1362-1366
GUO Yu, XU Peng, WANG Bei-di, LI Li-yang, GAO Shuang, KUANG Ye. The research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
Citation: GUO Yu, XU Peng, WANG Bei-di, LI Li-yang, GAO Shuang, KUANG Ye. The research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
shu

The research progress of serum tumor markers in the diagnosis of ovarian cancer

doi: 10.16766/j.cnki.issn.1674-4152.002061

  • Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China

Funds:

 320675018061

  • Received Date: 2021-01-05
    Available Online: 2022-02-16
    Abstract
  • Ovarian cancer (OC) is one of the three gynecological malignancies in the world. Due to the lack of obvious clinical symptoms and effective screening methods in early OC, the patients have a high fatality rate, and their prognosis is poor. In recent years, early detection of OC is the hot spot of research for the clinical and scientific research workers. Transvaginal ultrasound combined with biomarker detection is the most common screening strategy at now. Cancer antigen 125 (CA125) is a high molecular weight, highly glycosylated transmembrane mucin glycoprotein, which can be directly determined by immunoassay. It is currently the most widely used tumor protein marker, but the serology diagnosis for CA125 is lacking of sensitivity and specificity. At present, the exploration of new diagnostic targets is very urgent. Many serum tumor markers, including circulating tumor DNA (ctDNA), microRNA (miRNA) and circular RNA (circRNA), are attracting extensive attention of researchers. The combined detection of serum tumor markers has an important clinical significance. In-depth research on emerging tumor markers is not only conducive to early diagnosis and early treatment of OC, but help to promote the further exploration of mechanisms such as proliferation, invasion, metastasis, and drug resistance. This article aims to review the research progress of serum tumor markers with potential in the diagnosis of OC in recent years, in order to provide help for the early diagnosis of OC, increase the clinical detection rate, and improve the prognosis of patients.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    郎景和. 妇科恶性肿瘤筛查[J]. 中国实用妇科与产科杂志, 2016, 32(5): 385-389. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201605001.htm
    [2]
    TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
    [3]
    GUADAGNO E, PIGNATIELLO S, BORRELLI G, et al. Ovarian borderline tumors, a subtype of neoplasm with controversial behavior. Role of Ki67 as a prognostic factor[J]. Pathol Res Pract, 2019, 215(11): 152633. DOI: 10.1016/j.prp.2019.152633.
    [4]
    GIAMPAOLINO P, DELLA CORTE L, FORESTE V, et al. Unraveling a difficult diagnosis: The tricks for early recognition of ovarian cancer[J]. Minerva Med, 2019, 110(4): 279-291. http://www.researchgate.net/publication/333984344_Unraveling_a_difficult_diagnosis_the_tricks_for_early_recognition_of_ovarian_cancer
    [5]
    GUELI ALLETTI S, CAPOZZI V A, ROSATI A, et al. Laparoscopy vs. laparotomy for advanced ovarian cancer: A systematic review of the literature[J]. Minerva Med, 2019, 110(4): 341-357. http://www.researchgate.net/publication/334252526_Laparoscopy_vs_laparotomy_for_advanced_ovarian_cancer_a_systematic_review_of_the_literature
    [6]
    CHIOFALO B, BRUNI S, CERTELLI C, et al. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: Review of the literature and meta-analysis[J]. Minerva Med, 2019, 110(4): 330-340. http://www.researchgate.net/publication/334255809_Primary_debulking_surgery_vs_Interval_debulking_surgery_for_advanced_ovarian_cancer_Review_of_the_literature_and_meta-analysis
    [7]
    许艳, 徐灵, 索永刚, 等. 超声造影联合血清CA125、CA199、CEA对卵巢良恶性肿瘤的诊断价值[J]. 海南医学, 2020, 31(12): 1574-1576. doi: 10.3969/j.issn.1003-6350.2020.12.023
    [8]
    SHA R, BADHULIKA S. Recent advancements in fabrication of nanomaterial based biosensors for diagnosis of ovarian cancer: A comprehensive review[J]. Mikrochim Acta, 2020, 187(3): 181. doi: 10.1007/s00604-020-4152-8
    [9]
    JACOBS I J, MENON U, RYAN A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial[J]. Lancet, 2016, 387(10022): 945-956. doi: 10.1016/S0140-6736(15)01224-6
    [10]
    BLYUSS O, BURNELL M, RYAN A, et al. Comparison of Longitudinal CA125 algorithms as a first-line screen for ovarian cancer in the General Population[J]. Clin Cancer Res, 2018, 24(19): 4726-4733. doi: 10.1158/1078-0432.CCR-18-0208
    [11]
    TERRY K L, SCHOCK H, FORTNER R T, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort[J]. Clin Cancer Res, 2016, 22(18): 4664-4675. doi: 10.1158/1078-0432.CCR-16-0316
    [12]
    GRAYSON K, GREGORY E, KHAN G, et al. Urine Biomarkers for the early detection of ovarian cancer-are we there yet?[J]. Biomark Cancer, 2019, 11: 1179299X19830977. http://www.ncbi.nlm.nih.gov/pubmed/30833816
    [13]
    ASLAN K, ONAN M A, YILMAZ C, et al. Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses[J]. J Gynecol Obstet Hum Reprod, 2020, 49(5): 101713. doi: 10.1016/j.jogoh.2020.101713
    [14]
    LI B X, PU K, GE L, et al. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis[J]. Gene, 2019, 714: 143993. doi: 10.1016/j.gene.2019.143993
    [15]
    刘毓, 刘斌, 倾丽梅, 等. 循环肿瘤DNA在卵巢癌的应用进展[J]. 国际妇产科学杂志, 2019, 46(6): 688-692. doi: 10.3969/j.issn.1674-1870.2019.06.021
    [16]
    王东营, 吴飞, 张炜旸, 等. 循环肿瘤DNA在上皮性卵巢癌诊断及预后评估中的应用[J]. 中华全科医师杂志, 2018, 17(12): 1033-1037. doi: 10.3760/cma.j.issn.1671-7368.2018.12.021
    [17]
    ARILDSEN N S, MARTIN DE LA FUENTE L, MÅSBÄCK A, et al. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method[J]. Sci Rep, 2019, 9(1): 15506. doi: 10.1038/s41598-019-51697-6
    [18]
    TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: Genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J]. Med Sci(Basel), 2018, 6(2): 31. http://www.mdpi.com/2076-3271/6/2/31/pdf
    [19]
    WEISS A S, SWISHER E, PENNINGTON K P, et al. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years[J]. Gynecol Oncol, 2020, 159(1): 214-220. doi: 10.1016/j.ygyno.2020.06.509
    [20]
    MORIKAWA A, HAYASHI T, SHIMIZU M, et al. PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma[J]. Oncotarget, 2018, 9(20): 15266-15274. doi: 10.18632/oncotarget.24555
    [21]
    OGASAWARA A, HIHARA T, YABUNO A, et al. Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations[J]. Cancer Res Treat, 2020, 52(4): 1219-1228. http://www.researchgate.net/publication/341191336_Evaluation_of_Circulating_Tumor_DNA_in_Patients_with_Ovarian_Cancer_Harboring_Somatic_PIK3CA_or_KRAS_Mutations
    [22]
    WEIGELT B, COMINO-MÉNDEZ I, DE BRUIJN I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer[J]. Clin Cancer Res, 2017, 23(21): 6708-6720. doi: 10.1158/1078-0432.CCR-17-0544
    [23]
    KILLOCK D. Cancer SEEK and destroy a blood test for early cancer detection[J]. Nat Rev Clin Oncol, 2018, 15(6378): 133. http://smartsearch.nstl.gov.cn/paper_detail.html?id=eac87a40bd49dc089a0b2832682f49dd
    [24]
    HU Y B, ULRICH B C, SUPPLEE J, et al. False-positive plasma genotyping due to clonal hematopoiesis[J]. Clin Cancer Res, 2018, 24(18): 4437-4443. doi: 10.1158/1078-0432.CCR-18-0143
    [25]
    ABOUTALEBI H, BAHRAMI A, SOLEIMANI A, et al. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer[J]. Int J Biochem Cell Biol, 2020, 124: 105765. DOI: 10.1016/j.biocel.2020.105765.
    [26]
    FENG Y W, HANG W Z, SANG Z Y, et al. Identification of exosomal and non exosomal microRNAs associated with the drug resistance of ovarian cancer[J]. Mol Med Rep, 2019, 19(5): 3376-3392. http://www.onacademic.com/detail/journal_1000042324685099_c12b.html
    [27]
    CHEN M W, YANG S T, CHIEN M H, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer[J]. Cancer Res, 2017, 77(8): 1955-1967. doi: 10.1158/0008-5472.CAN-16-1115
    [28]
    DUAN S F, DONG X C, HAI J, et al. MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2[J]. Biomed Pharmacother, 2018, 107: 712-720. doi: 10.1016/j.biopha.2018.08.044
    [29]
    DONG P X, XIONG Y, WATARI H, et al. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells[J]. J Exp Clin Cancer Res, 2016, 35(1): 132. doi: 10.1186/s13046-016-0415-y
    [30]
    EOH K J, LEE S H, KIM H J, et al. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis[J]. Biochem Biophys Res Commun, 2018, 497(2): 513-520. doi: 10.1016/j.bbrc.2018.02.062
    [31]
    YOKOI A, YOSHIOKA Y, HIRAKAWA A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer[J]. Oncotarget, 2017, 8(52): 89811-89823. doi: 10.18632/oncotarget.20688
    [32]
    汪义泳, 管玉宇, 杜景云, 等. 生物分子标记物在卵巢癌早期诊断中的研究进展[J]. 河北医药, 2019, 41(18): 2855-2860, 2865. doi: 10.3969/j.issn.1002-7386.2019.18.035
    [33]
    PALIWAL N, VASHIST M, CHAUHAN M. Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer[J]. 3Biotech, 2020, 10(3): 142. doi: 10.1007/s13205-020-2124-7?utm_source=trendmd
    [34]
    MENG X D, MVLLER V, MILDE-LANGOSCH K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer[J]. Oncotarget, 2016, 7(13): 16923-16935. doi: 10.18632/oncotarget.7850
    [35]
    ELIAS K M, FENDLER W, STAWISKI K, et al. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer[J]. ELife, 2017, 6: e28932. doi: 10.7554/eLife.28932
    [36]
    杨维娜, 徐燕颖. 长链非编码RNA在卵巢癌中的研究进展[J]. 山东医药, 2020, 60(29): 91-93. doi: 10.3969/j.issn.1002-266X.2020.29.027
    [37]
    郑媛媛, 李伟, 陈余清. 环状RNA与肿瘤相关性研究进展[J]. 中华全科医学, 2019, 17(7): 1181-1185. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201907035.htm
    [38]
    CUI X L, WANG J X, GUO Z J, et al. Emerging function and potential diagnostic value of circular RNAs in cancer[J]. Mol Cancer, 2018, 17(1): 123. doi: 10.1186/s12943-018-0877-y
    [39]
    SHENG J Q, LIU L, WANG M R, et al. Circular RNAs in digestive system cancer: Potential biomarkers and therapeutic targets[J]. Am J Cancer Res, 2018, 8(7): 1142-1156. http://www.ajcr.us/files/ajcr0080004.pdf
    [40]
    CHEN Q, ZHANG J, HE Y, et al. Hsa_circ_0061140 knockdown reverses FOXM1-mediated cell growth and metastasis in ovarian cancer through miR-370 sponge activity[J]. Mol Ther Nucleic Acids, 2018, 13: 55-63. doi: 10.1016/j.omtn.2018.08.010
    [41]
    CHEN H, MAO M, JIANG J, et al. Circular RNA CDR1as acts as a sponge of miR-135b-5p to suppress ovarian cancer progression[J]. Onco Targets Ther, 2019, 12: 3869-3879. doi: 10.2147/OTT.S207938
    [42]
    LIU H, HU Y, ZHUANG B, et al. Differential expression of circRNAs in embryonic heart tissue associated with ventricular septal defect[J]. Int J Med Sci, 2018, 15(7): 703-712. doi: 10.7150/ijms.21660
    [43]
    KAREDATH T, AHMED I, AL AMERI W, et al. Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes[J]. BMC Cancer, 2019, 19(1): 565. doi: 10.1186/s12885-019-5723-0
    [44]
    BAO L, ZHONG J, PANG L. Upregulation of circular RNA VPS13C-has-circ-001567 promotes ovarian cancer cell proliferation and invasion[J]. Cancer Biother Radiopharm, 2019, 34(2): 110-118. doi: 10.1089/cbr.2018.2641
    [45]
    QIU L, XU H, JI M, et al. Circular RNAs in hepatocellular carcinoma: Biomarkers, functions and mechanisms[J]. Life Sci, 2019, 231: 116660. doi: 10.1016/j.lfs.2019.116660
    [46]
    FAN C M, WANG J P, TANG Y Y, et al. CircMAN 1A2 could serve as a novel serum biomarker for malignant tumors[J]. Cancer Sci, 2019, 110(7): 2180-2188. doi: 10.1111/cas.14034
    [47]
    XIE J, WANG S F, LI G L, et al. CircEPSTI1 regulates ovarian cancer progression via decoying miR-942[J]. J Cell Mol Med, 2019, 23(5): 3597-3602. doi: 10.1111/jcmm.14260
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (164) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return